Meiji Seika Pharma initiates a Phase I trial in Australia evaluating ME3241, an anti-PD-1 agonist antibody discovered with FBRI.
Ohio Startup Opens Orders for At-Home Cognitive Enhancement Device While Advancing Separate Clinical Trials U's ...
These brain areas are also linked to impulsivity and emotional control in people with ADHD. By reducing food cravings and constant thoughts about eating, GLP-1s may help some people feel more focused ...
Vitestro's ARPD blood-drawing robot gained an EU CE mark in 2024 and launched in the healthcare settings across the region in March 2025.
Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for ...
A new study published in the journal of Autoimmunity Reviews that Hyaluronic acid (HA) fillers seem to be a safe, minimally invasive treatment for improving both functional and aesthetic ...
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of ...
The FDA expands Palynziq approval to include pediatric patients aged 12 years and older with phenylketonuria and uncontrolled blood Phe levels.
Gepotidacin and nitrofurantoin demonstrate similar efficacy in reducing symptom severity and restoring daily function in women with uncomplicated UTI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results